Table of Contents
ISRN Pharmacology
Volume 2012 (2012), Article ID 130347, 7 pages
http://dx.doi.org/10.5402/2012/130347
Research Article

Short-Term Therapy with Rosiglitazone, a PPAR- 𝜸 Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

1Calderstones School, Harthill Road, Liverpool L18 3HS, UK
2Department of Health Sciences, Liverpool Hope University, Hope Park, Liverpool L16 9JD, UK

Received 19 May 2012; Accepted 21 June 2012

Academic Editors: H. Cerecetto, K. Lutfy, and F. G. M. Russel

Copyright © 2012 Mohammad M. Naderali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988. View at Google Scholar · View at Scopus
  2. L. Capron, J. Jarnet, S. Kazandjian, and E. Housset, “Growth-promoting effects of diabetes and insulin on arteries. An in vivo study of rat aorta,” Diabetes, vol. 35, no. 9, pp. 973–978, 1986. View at Google Scholar · View at Scopus
  3. E. A. Anderson, T. W. Balon, R. P. Hoffman, and S. A. Sinkey, “Marked hyperinsulinaemia produces both sympathic nueral activation and vasodilataion in normal humans,” The Journal of Clinical Investigation, vol. 87, pp. 2246–2252, 1991. View at Google Scholar
  4. M. Laakso, S. V. Edelman, G. Brechtel, and A. D. Baron, “Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM,” Diabetes, vol. 41, no. 9, pp. 1076–1083, 1992. View at Google Scholar · View at Scopus
  5. E. K. Naderali, M. J. Brown, L. C. Pickavance, J. P. H. Wilding, P. J. Doyle, and G. Williams, “Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols,” Clinical Science, vol. 101, no. 5, pp. 499–506, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. G. E. McVeigh, G. M. Brennan, G. D. Johnston et al., “Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus,” Diabetologia, vol. 35, no. 8, pp. 771–776, 1992. View at Google Scholar · View at Scopus
  7. G. F. Watts, S. F. O'Brien, W. Silvester, and J. A. Millar, “Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia,” Clinical Science, vol. 91, no. 5, pp. 567–573, 1996. View at Google Scholar · View at Scopus
  8. A. M. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf et al., “Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 9, pp. 1756–1764, 1997. View at Google Scholar · View at Scopus
  9. Y. Miyazaki, A. Mahankali, M. Matsuda et al., “Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone,” Diabetes Care, vol. 24, no. 4, pp. 710–719, 2001. View at Google Scholar · View at Scopus
  10. L. C. Pickavance, M. Tadayyon, P. S. Widdowson, R. E. Buckingham, and J. P. H. Wilding, “Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution,” British Journal of Pharmacology, vol. 128, no. 7, pp. 1570–1576, 1999. View at Google Scholar · View at Scopus
  11. S. L. Suter, J. J. Nolan, P. Wallace, B. Gumbiner, and J. M. Olefsky, “Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects,” Diabetes Care, vol. 15, no. 2, pp. 193–203, 1992. View at Google Scholar · View at Scopus
  12. S. Kumar, A. J. M. Boulton, H. Beck-Nielsen et al., “Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients,” Diabetologia, vol. 39, no. 6, pp. 701–709, 1996. View at Google Scholar · View at Scopus
  13. S. Yoshioka, H. Nishino, T. Shiraki et al., “Antihypertensive effects of CS-045 treatment in obese Zucker rats,” Metabolism, vol. 42, no. 1, pp. 75–80, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Yoshimoto, M. Naruse, M. Nishikawa et al., “Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats,” American Journal of Physiology, vol. 272, no. 6, pp. E989–E996, 1997. View at Google Scholar · View at Scopus
  15. T. A. Buchanan, W. P. Meehan, Y. Y. Jeng et al., “Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect,” The Journal of Clinical Investigation, vol. 96, no. 1, pp. 354–360, 1995. View at Google Scholar · View at Scopus
  16. J. C. Sartori-Valinotti, M. R. Venegas-Pont, B. B. LaMarca et al., “Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats,” Steroids, vol. 75, no. 11, pp. 794–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. G. de Oliveira Silva-Junior, T. da Silva Torres, L. de Souza Mendonca, and C. Alberto Mandarim-de-Lacerda Carlos, “Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats,” Experimental and Toxicologic Pathology, vol. 63, no. 1-2, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. B. Walker, P. D. Chattington, R. E. Buckingham, and G. Williams, “The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats,” Diabetes, vol. 48, no. 7, pp. 1448–1453, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Verma, S. Bhanot, E. Arikawa, L. Yao, and J. H. McNeill, “Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats,” Pharmacology, vol. 56, no. 1, pp. 7–16, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. K. K. Naka, K. Papathanassiou, A. Bechlioulis et al., “Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin,” Diabetes and Vascular Disease Research, vol. 8, no. 3, pp. 195–201, 2011. View at Google Scholar
  21. K. K. Naka, K. Papathanassiou, A. Bechlioulis et al., “Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas,” Diabetes and Vascular Disease Research, vol. 9, no. 1, pp. 52–58, 2009. View at Google Scholar
  22. K. L. Christensen and M. J. Mulvany, “Mesenteric arcade arteries contribute substantially to vascular resistance in conscious rats,” Journal of Vascular Research, vol. 30, no. 2, pp. 73–79, 1993. View at Google Scholar · View at Scopus
  23. E. K. Naderali, P. J. Doyle, and G. Williams, “Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs,” Clinical Science, vol. 98, no. 5, pp. 537–543, 2000. View at Google Scholar · View at Scopus
  24. A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank, “Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress inpatients with type 2 diabetes mellitus,” Vascular Medicine, vol. 12, no. 4, pp. 311–318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Tian, W. T. Wong, X. Y. Tian, P. Zhang, Y. Huang, and N. Wang, “Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin b receptor,” Hypertension, vol. 56, no. 1, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. R. E. Law, S. Goetze, X. P. Xi et al., “Expression and function of PPARγ in rat and human vascular smooth muscle cells,” Circulation, vol. 101, no. 11, pp. 1311–1318, 2000. View at Google Scholar · View at Scopus
  27. A. B. Walker, E. K. Naderali, P. D. Chattington, R. E. Buckingham, and G. Williams, “Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro,” Diabetes, vol. 47, no. 5, pp. 810–814, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Lu, X. Guo, S. K. Karathanasis et al., “Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats,” Cardiovascular Diabetology, vol. 9, article 19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Liang, Y. Ren, H. Tan et al., “Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products,” British Journal of Pharmacology, vol. 158, no. 8, pp. 1865–1873, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Wang, J. D. Symons, H. Zhang, Z. Jia, F. J. Gonzalez, and T. Yang, “Distinct functions of vascular endothelial and smooth muscle PPARγ in regulation of blood pressure and vascular tone,” Toxicologic Pathology, vol. 37, no. 1, pp. 21–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Wang, J. L. Jiang, C. P. Hu, X. J. Zhang, D. L. Yang, and Y. J. Li, “Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells,” Diabetes/Metabolism Research and Reviews, vol. 23, no. 2, pp. 157–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. J. Nicol, M. Adachi, T. E. Akiyama, and F. J. Gonzalez, “PPARγ in endothelial cells influences high fat diet-induced hypertension,” American Journal of Hypertension, vol. 18, no. 4, pp. 549–556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Onuta, J. L. Hillebrands, H. Rienstra et al., “Dichotomous effects of rosiglitazone in transplantation-induced systemic vasodilator dysfunction in rats,” Transplantation, vol. 85, no. 4, pp. 582–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. B. Majithiya, A. N. Parmar, C. J. Trivedi, and R. Balaraman, “Effect of pioglitazone on L-NAME induced hypertension in diabetic rats,” Vascular Pharmacology, vol. 43, no. 4, pp. 260–266, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. J. B. Majithiya, A. N. Paramar, and R. Balaraman, “Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats,” Cardiovascular Research, vol. 66, no. 1, pp. 150–161, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Bagi, A. Koller, and G. Kaley, “PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes,” American Journal of Physiology, vol. 286, no. 2, pp. H742–H748, 2004. View at Google Scholar · View at Scopus
  37. L. Tao, Y. Wang, E. Gao et al., “Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction,” Circulation Research, vol. 106, no. 2, pp. 409–417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. K. B. Sotiropoulos, A. Clermont, Y. Yasuda et al., “Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain,” The FASEB Journal, vol. 20, no. 8, pp. 1203–1205, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Ren, N. Liu, H. Zhi et al., “Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro,” Cardiovascular Diabetology, vol. 10, no. 1, article 10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” The Lancet, vol. 373, no. 9681, pp. 2125–2135, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. V. Hernandez, A. Usmani, A. Rajamanickam, and A. Moheet, “Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials,” American Journal of Cardiovascular Drugs, vol. 11, no. 2, pp. 115–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. K. Loke, C. S. Kwok, and S. Singh, “Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies,” British Medical Journal, vol. 342, p. d1309, 2011. View at Publisher · View at Google Scholar · View at Scopus